Favorable Results Seen With APX005M in Combination Therapy for Metastatic Ductal Pancreatic Adenocarcinoma

April 4, 2019
Mark H. O'Hara, MD

Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.

Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.

Related Content:

AACR | Pancreatic Cancer